Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease

Summary

CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease in Crohn's Disease Activity Index (CDAI).

Timeline

Start

2002-12

Primary completion

2004-07

Completion

2004-09

Drugs

Indications